Please assess the completion status of the following clinical trial:

Trial Title: TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed extensive-stage SCLC~* Disease control after the first line platinum/etoposide treatment~* ECOG performance status of 0 or 1~* Measurable disease according to RECIST Version 1.1 criteria~* Adequate bone marrow, liver, and renal function.~* Formalin Fixed Paraffin Embedded (FFPE) or frozen tumor tissue material must be available.~* Resolution of any toxic effects of prior therapy according to NCI CTCAE, v 4.0~* Full recovery from significant complications of the surgery~* If childbearing age, use of double-barrier contraceptive measures, oral or abstaining from sexual intercourse during the study and up to 90 days after the last dose of chemotherapy~* Negative pregnancy test within 72 hours prior to the initiation of study treatment, if of childbearing potential~* Signed informed consent prior to beginning protocol specific procedures~* Patients must be available for treatment and follow-up~Exclusion Criteria:~* Previous therapies with Tivantinib or other known c-MET inhibitor~* Radiotherapy for target lesions and major surgical procedure within 4 weeks, prior to the inclusion in the study~* Palliative radiotherapy within 2 weeks prior to the inclusion in the study~* History of malignancy in the past five years, excluding basal cell the cervix, prostate cancer with a value of prostate-specific antigen \<0.2 ng / mL~* History of cardiac disease~* Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections~* Pregnant or lactating women or childbearing/reproductive potential not using adequate contraception~* Need for breastfeeding during or within 12 weeks of completion of the study~* Gastrointestinal disorders that may interfere with the absorption of Tivantinib~* Inability or unwillingness to swallow the complete doses of Tivantinib~* Any known contraindication to treatment and other significant comorbid conditions which could jeopardize participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARQ-197 (Type: EXPERIMENTAL): ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).